ReVia and Sitagliptin Phosphate

• Generic Name: naltrexone
• Dosage Forms: tablet, film coated
• Other Brand Names: ReVia, Depade, Vivitrol

ReVia blocks the effects of opioid medication, including pain relief or feelings of well-being that can lead to opioid abuse. An opioid is sometimes called a narcotic. This medicine is used as part of a treatment program for drug or alcohol dependence.

ReVia is used to prevent relapse in people who became dependent on opioid medicine and then stopped using it. This medicine can help keep you from feeling a "need" to use the opioid.

ReVia is also used to treat alcoholism by reducing your urge to drink alcohol. This may help you drink less or stop drinking completely. This medicine will not cause you to "sober up" and will not decrease the effects of alcohol you recently consumed.

ReVia is not a cure for drug addiction or alcoholism.

ReVia may also be used for purposes not listed in this medication guide.

• Generic Name: sitagliptin
• Dosage Forms: n.a.
• Other Brand Names: Januvia

Used as monotherapy as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.

Used in combination with immediate- or extended-release metformin given separately or as a fixed combination (Janumet or Janumet XR, respectively) as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.

Used in fixed combination with ertugliflozin (Steglujan) as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus when treatment with both drugs is appropriate.

Used in combination with other oral antidiabetic agents (e.g., metformin, a sulfonylurea, a thiazolidinedione [peroxisome proliferator-activated receptor-γ agonist]) or insulin as an adjunct to diet and exercise in patients with type 2 diabetes mellitus who have not achieved adequate glycemic control with one or more oral antidiabetic agents and/or insulin.

American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) suggests a DPP-4 inhibitor as one of several alternatives for initial monotherapy in patients with metformin contraindications (e.g., renal disease, hepatic disease, GI intolerance, risk of lactic acidosis). DPP-4 inhibitors also recommended as part of combination therapy, particularly with both postprandial and fasting plasma glucose elevations.

Not indicated for use in patients with type 1 diabetes mellitus or diabetic ketoacidosis; insulin is required in these conditions.